Data analysis and navigation in high-dimensional chemical and biological spaces

The goal of this master thesis is to develop and validate a visual data-mining approach suitable for the screening of chemicals in the context of REACH [Registration, Evaluation, Authorization and Restriction of Chemicals]. The proposed approach will facilitate the development and validation of non-testing methods via the exploration of environmental endpoints and their relationship with the chemical structure and physicochemical properties of chemicals. The use of an interactive chemical space data exploration tool using 3D visualization and navigation will enrich the information available with additional variables like size, texture and color of the objects of the scene (compounds). The features that distinguish this approach and make it unique are (i) the integration of multiple data sources allowing the recovery in real time of complementary information of the studied compounds, (ii) the integration of several algorithms for the data analysis (dimensional reduction, generation of composite variables and clustering) and (iii) direct user interaction with the data through the virtual navigation mechanism. All this is achieved without the need for specialized hardware or the use of specific devices and high-cost virtual reality and mixed reality

Computational Deorphaning of <em>Mycobacterium tuberculosis</em> Targets

Tuberculosis (TB) continues to be a major health hazard worldwide due to the resurgence of drug discovery strains of Mycobacterium tuberculosis (Mtb) and co-infection. For decades drug discovery has concentrated on identifying ligands for ~10 Mtb targets, hence most of the identified essential proteins are not utilised in TB chemotherapy. Here computational techniques were used to identify ligands for the orphan Mtb proteins. These range from ligand-based and structure-based virtual screening modelling the proteome of the bacterium. Identification of ligands for most of the Mtb proteins will provide novel TB drugs and targets and hence address drug resistance, toxicity and the duration of TB treatment

Computational de-orphaning of Mycobacterium tuberculosis targets

Tuberculosis (TB) continues to be a major health hazard worldwide due to the resurgence of drug discovery strains of Mycobacterium tuberculosis (Mtb) and co-infection. For decades drug discovery has concentrated on identifying ligands for ~10 Mtb targets, hence most of the identified essential proteins are not utilised in TB chemotherapy. Here computational techniques were used to identify ligands for the orphan Mtb proteins. These range from ligand-based and structure-based virtual screening modelling the proteome of the bacterium. Identification of ligands for most of the Mtb Proteins will provide novel TB drugs and targets and hence address drug resistance, toxicity and the duration of TB treatment

Fast Monte Carlo Simulation for Patient-specific CT/CBCT Imaging Dose Calculation

Recently, X-ray imaging dose from computed tomography (CT) or cone beam CT (CBCT) scans has become a serious concern. Patient-specific imaging dose calculation has been proposed for the purpose of dose management. While Monte Carlo (MC) dose calculation can be quite accurate for this purpose, it suffers from low computational efficiency. In response to this problem, we have successfully developed a MC dose calculation package, gCTD, on GPU architecture under the NVIDIA CUDA platform for fast and accurate estimation of the x-ray imaging dose received by a patient during a CT or CBCT scan. Techniques have been developed particularly for the GPU architecture to achieve high computational efficiency. Dose calculations using CBCT scanning geometry in a homogeneous water phantom and a heterogeneous Zubal head phantom have shown good agreement between gCTD and EGSnrc, indicating the accuracy of our code. In terms of improved efficiency, it is found that gCTD attains a speed-up of ~400 times in the homogeneous water phantom and ~76.6 times in the Zubal phantom compared to EGSnrc. As for absolute computation time, imaging dose calculation for the Zubal phantom can be accomplished in ~17 sec with the average relative standard deviation of 0.4%. Though our gCTD code has been developed and tested in the context of CBCT scans, with simple modification of geometry it can be used for assessing imaging dose in CT scans as well.Comment: 18 pages, 7 figures, and 1 tabl

Computational Methods for Structure-Activity Relationship Analysis and Activity Prediction

Structure-activity relationship (SAR) analysis of small bioactive compounds is a key task in medicinal chemistry. Traditionally, SARs were established on a case-by-case basis. However, with the arrival of high-throughput screening (HTS) and synthesis techniques, a surge in the size and structural heterogeneity of compound data is seen and the use of computational methods to analyse SARs has become imperative and valuable. In recent years, graphical methods have gained prominence for analysing SARs. The choice of molecular representation and the method of assessing similarities affects the outcome of the SAR analysis. Thus, alternative methods providing distinct points of view of SARs are required. In this thesis, a novel graphical representation utilizing the canonical scaffold-skeleton definition to explore meaningful global and local SAR patterns in compound data is introduced. Furthermore, efforts have been made to go beyond descriptive SAR analysis offered by the graphical methods. SAR features inferred from descriptive methods are utilized for compound activity predictions. In this context, a data structure called SAR matrix (SARM), which is reminiscent of conventional R-group tables, is utilized. SARMs suggest many virtual compounds that represent as of yet unexplored chemical space. These virtual compounds are candidates for further exploration but are too many to prioritize simply on the basis of visual inspection. Conceptually different approaches to enable systematic compound prediction and prioritization are introduced. Much emphasis is put on evolving the predictive ability for prospective compound design. Going beyond SAR analysis, the SARM method has also been adapted to navigate multi-target spaces primarily for analysing compound promiscuity patterns. Thus, the original SARM methodology has been further developed for a variety of medicinal chemistry and chemogenomics applications

A Machine Learning Approach for the Identification of a Treatment against Chagas Disease

In this final degree project we have presented a machine learning approach to predict the biological activity of FDA approved drugs against T. cruzi. We believe that the proposed methodology will expand the state-of-art of machine learning in the Chagas disease drug discovery pipeline. We have obtained similar performance results with the work presented in but applied only to FDA approved drugs as a repurposing strategy. A final contribution of this work is the biological evaluation provided by the metabolic pathway analysis. This evaluation allows us to map FDA approved drugs onto T. cruzi metabolic pathways. This validation is useful because it incorporates important informa tion of how the drugs target T. cruzi. Finding a subset of drugs that come up from differently motivated experiments is promising. The fact that among our results are drugs that already have been tested in the past against Chagas disease is encouraging evidence that our approaches are able to produce reasonable candidates for drug repurposing. Additionally, the majority of the drugs present in our results were never tested against T. cruzi, confirming the novelty of our approaches.CONACYT – Consejo Nacional de Ciencia y TecnologíaPROCIENCI

Mycobacterial dihydrofolate reductase inhibitors identified using chemogenomic methods and in vitro validation.

The lack of success in target-based screening approaches to the discovery of antibacterial agents has led to reemergence of phenotypic screening as a successful approach of identifying bioactive, antibacterial compounds. A challenge though with this route is then to identify the molecular target(s) and mechanism of action of the hits. This target identification, or deorphanization step, is often essential in further optimization and validation studies. Direct experimental identification of the molecular target of a screening hit is often complex, precisely because the properties and specificity of the hit are not yet optimized against that target, and so many false positives are often obtained. An alternative is to use computational, predictive, approaches to hypothesize a mechanism of action, which can then be validated in a more directed and efficient manner. Specifically here we present experimental validation of an in silico prediction from a large-scale screen performed against Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis. The two potent anti-tubercular compounds studied in this case, belonging to the tetrahydro-1,3,5-triazin-2-amine (THT) family, were predicted and confirmed to be an inhibitor of dihydrofolate reductase (DHFR), a known essential Mtb gene, and already clinically validated as a drug target. Given the large number of similar screening data sets shared amongst the community, this in vitro validation of these target predictions gives weight to computational approaches to establish the mechanism of action (MoA) of novel screening hit

Technological developments in Virtual Screening for the discovery of small molecules with novel mechanisms of action

Programa de Doctorat en Recerca, Desenvolupament i Control de Medicaments[eng] Advances in structural and molecular biology have favoured the rational development of novel drugs thru structure-based drug design (SBDD). Particularly, computational tools have proven to be rapid and efficient tools for hit discovery and optimization. The main motivation of this thesis is to improve and develop new methods in the area of computer-based drug discovery in order to study challenging targets. Specifically, this thesis is focused on docking and Virtual Screening (VS) methodologies to be able to exploit non-standard sites, like protein-protein interfaces or allosteric sites, and discover bioactive molecules with novel mechanisms of action. First, I developed an automatic pipeline for binding mode prediction that applies knowledge- based restraints and validated the approach by participating in the CELPP Challenge, a blind pose prediction challenge. The aim of the first VS in this thesis is to find small molecules able to not only disrupt the RANK-RANKL interaction but also inhibit the constitutive activation of the receptor. With a combination of computational, biophysical, and cell-based assays we were able to identify the first small molecule binders for RANK that could be used as a treatment for Triple Negative Breast Cancer. When working with challenging targets, or with non-standard mechanisms of action, the relationship between binding and the biological response is unpredictable, because the biological response (if any) will depend on the biological function of the particular allosteric site, which is generally unknown. For this reason, we then tested the applicability of the combination of ultrahigh-throughput VS with low-throughput high content assay. This allowed us to characterize a novel allosteric pocket in PTEN and also describe the first allosteric modulators for this protein. Finally, as the accessible Chemical Space grows at a rapid pace, we developed an algorithm to efficiently explore ultra-large Chemical Collections using a Bottom-up approach. We prospectively validated the approach in BRD4 and identified novel BRD4 inhibitors with an affinity comparable to advanced drug candidates for this target.[spa] Els avenços en biologia estructural i molecular han afavorit el desenvolupament racional de nous fàrmacs a través del disseny de fàrmacs basat en l'estructura (SBDD). En particular, les eines computacionals han demostrat ser ràpides i eficients per al descobriment i l'optimització de fàrmacs. La principal motivació d'aquesta tesi és millorar i desenvolupar nous mètodes en l'àrea del descobriment de fàrmacs per ordinador per tal d'estudiar proteïnes complexes. Concretament, aquesta tesi se centra en les metodologies d'acoblament i de cribratge virtual (CV) per poder explotar llocs no estàndard, com interfícies proteïna-proteïna o llocs al·lostèrics, i descobrir molècules bioactives amb nous mecanismes d'acció. En primer lloc, vaig desenvolupar un protocol automàtic per a la predicció del mode d’unió aplicant restriccions basades en el coneixement i vaig validar l'enfocament participant en el repte CELPP, un repte de predicció del mode d’unió a cegues. L'objectiu del primer CV d'aquesta tesi és trobar petites molècules capaces no només d'interrompre la interacció RANK-RANKL sinó també d'inhibir l'activació constitutiva del receptor. Amb una combinació d'assajos computacionals, biofísics i basats en cèl·lules, vam poder identificar les primeres molècules petites per a RANK que es podrien utilitzar com a tractament per al càncer de mama triple negatiu. Quan es treballa amb proteïnes complexes, o amb mecanismes d'acció no estàndard, la relació entre la unió i la resposta biològica és impredictible, perquè la resposta biològica (si n'hi ha) dependrà de la funció biològica del lloc al·lostèric particular, que generalment és desconeguda. Per aquest motiu, després vam provar l'aplicabilitat de la combinació de CV d'alt rendiment amb assaig de contingut alt de baix rendiment. Això ens va permetre caracteritzar un nou lloc d’unió al·lostèric en PTEN i també descriure els primers moduladors al·lostèrics d'aquesta proteïna. Finalment, a mesura que l'espai químic accessible creix a un ritme ràpid, hem desenvolupat un algorisme per explorar de manera eficient col·leccions de productes químics molt grans mitjançant un enfocament de baix a dalt. Vam validar aquest enfocament amb BRD4 i vam identificar nous inhibidors de BRD4 amb una afinitat comparable als candidats a fàrmacs més avançats per a aquesta proteïna